SAMSARA BIOCAPITAL
Samsara Biocapital, LLC provides investment advisory services.
SAMSARA BIOCAPITAL
Social Links:
Industry:
Financial Services
Founded:
2016-09-23
Status:
Active
Contact:
1-650-285-4270
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Cash App
Cash App is the fastest growing financial brand in the world.
Northpond Ventures
Northpond Ventures is a science-driven project capital ๏ฌrm that focuses on biotechnology and a๏ฌliated industries.
RA Capital Management
RA Capital Management is an investment advisor specializing in the life-sciences and drug development sectors.
Walden International
Walden International is a venture capital firm.
Current Employees Featured
Marcos Milla
Marcos Milla Venture Partner @ Samsara BioCapital Venture Partner
Srinivas Akkaraju
Srinivas Akkaraju Founder & Managing Partner @ Samsara BioCapital Founder & Managing Partner 2017-01-01
Mike Dybbs
Mike Dybbs Partner @ Samsara BioCapital Partner 2017-01-01
Stephen Shuttleworth
Stephen Shuttleworth Venture Partner @ Samsara BioCapital Venture Partner 2019-01-01
Founder
Srinivas Akkaraju
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2022-09-08 | Autobahn Therapeutics | Samsara BioCapital investment in Venture Round - Autobahn Therapeutics | 32.7 M USD |
2022-07-18 | Delfi Diagnostics | Samsara BioCapital investment in Series B - Delfi Diagnostics | 225 M USD |
2022-06-29 | MiroBio | Samsara BioCapital investment in Series B - MiroBio | 80 M GBP |
2022-06-17 | Scholar Rock | Samsara BioCapital investment in Post-IPO Equity - Scholar Rock | 205 M USD |
2022-06-08 | Mineralys Therapeutics | Samsara BioCapital investment in Series B - Mineralys Therapeutics | 118 M USD |
2022-06-07 | ImmunOs Therapeutics | Samsara BioCapital investment in Series B - ImmunOs Therapeutics | 71 M CHF |
2022-06-02 | Upstream Bio | Samsara BioCapital investment in Series A - Upstream Bio | 200 M USD |
2022-04-08 | Lyra Therapeutics | Samsara BioCapital investment in Post-IPO Equity - Lyra Therapeutics | 100.5 M USD |
2022-02-22 | Eyebiotech | Samsara BioCapital investment in Series A - Eyebiotech | 65 M USD |
2022-02-09 | Seismic Therapeutic | Samsara BioCapital investment in Series A - Seismic Therapeutic | 101 M USD |
Key Employee Changes
Date | New article |
---|---|
2020-03-05 | ElevateBio Appoints Kareem Reda as Chief Business Officer |